Standard BioTools Inc. reports developments in life-science research tools built around proprietary mass cytometry and microfluidics technologies. The company sells instruments, consumables and services for genomics, single-cell proteomics and spatial proteomics, including platforms such as Biomark X9, CyTOF XT and Hyperion systems used in research workflows.
Recurring news includes operating and financial results, capital-structure updates, shareholder voting and governance matters, portfolio actions following the completed sale of SomaLogic assets, and collaborations that expand imaging mass cytometry and multi-omic research applications. Company updates also describe translational and clinical research use cases in oncology, immunology and immunotherapy, with products positioned for research use rather than diagnostic procedures.
Standard BioTools Inc. (Nasdaq:LAB) announced it will report its second quarter 2022 financial results on August 8, 2022, after market close. The company, known for its mission to enhance human health through advanced technologies, is set to host a conference call at 1:30 p.m. PT to discuss its financial outcomes and operational progress. Interested parties can listen via phone or through a live webcast on the company's Investor Relations page.
Standard BioTools Inc. (Nasdaq:LAB) reported first-quarter 2022 financial results with total revenue of $26.5 million, down from $32.8 million in Q1 2021, primarily due to lower COVID-19 revenue. The GAAP net loss was $76.3 million, significantly higher than a net loss of $18.8 million in Q1 2021, while non-GAAP net loss also increased to $19.5 million from $11.1 million. The company secured a $250 million capital infusion from Casdin Capital and Viking Global, aimed at enhancing operations and growth strategies amidst ongoing sales disruptions and COVID-19 impacts.
Standard BioTools Inc. (Nasdaq:LAB) will announce its first quarter 2022 financial results on May 5, 2022, after market close. A conference call will be held at 2:00 p.m. PT to discuss these results and operational progress. Notably, the recent appointment of new management members follows a $250 million strategic capital infusion, leading to a 90-day assessment period without a Q&A session. The company focuses on advancing tools for biomedical research, highlighting its commitment to improving human health and efficiency in drug development.
Standard BioTools Inc. (Nasdaq:LAB) has launched the Hyperion+™ Imaging System, enhancing high-plex spatial imaging capabilities with a 1.6x lower limit of detection and the ability to process over 100 samples per week. This system enables researchers to uncover critical insights into disease mechanisms and therapeutic responses, significantly accelerating translational research. Key advantages include faster results, up to 10x cost savings compared to conventional methods, and the capacity for high-quality data generation with minimal autofluorescence. The system was unveiled at the AACR annual meeting in New Orleans.
Standard BioTools Inc. announced the grant of equity inducement awards to new executives, including Michael Egholm as CEO, Hanjoon Kim as COO, and Ardalan Arfaei as Senior VP. The Compensation Committee approved stock options and restricted stock units (RSUs) to incentivize their employment, with awards comprising millions of shares. The options have a 10-year term with an exercise price of $3.99 per share, vesting over four years. Standard BioTools aims to accelerate breakthroughs in human health using innovative technologies in biomedical research.
Summary not available.